Company intelligence / Profile preview

Qaam

Ownership: Private
Development stage: Other

Overview

Qaam is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics. The company leverages a proprietary drug discovery platform to identify and optimize candidates for challenging targets in oncology. While currently in the pre-clinical phase, Qaam aims to advance a pipeline of precision medicines designed to address significant unmet needs in cancer treatment. The company's approach combines advanced computational methods with traditional medicinal chemistry to accelerate the development of its lead programs.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Qaam.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qaam.

Explore the full profile